All In Biotech

Drug Trial Radar · NCT05393440

First-in-human (FIH) Phase I Trial of BS-006 in Cervical Cancer

A First-in-human Phase I Two-stage Clinical Trial for Intratumoral Injection of Recombinant Oncolytic Type II Herpes Simplex Virus (BS-006) in Patients With Recurrent Cervical Cancer

Last checked: Nov 19, 2026Latest source record: Apr 7, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

18

Planned (sponsor's estimate)

Start

Sep 16, 2022

Primary completion

Dec 31, 2023

Study completion Jul 1, 2024

Sponsor

Lead sponsor
Zhongnan HospitalAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Binhui Biopharmaceutical Co., Ltd.
First posted
May 26, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Female only, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a two-stage phase I clinical trial with oncolytic viruses BS-006 in recurrent or metastasis cervical cancer patients who failed in second line treatment.

Conditions

  • Uterine Cervical Neoplasms

Interventions

  • BS-006Biological

    BS-006 is an engineered recombinant type II herpes simplex virus (HSV2) designed and produced by Wuhan Binhui Biopharmaceutical Co., Ltd. It was derived from HSV2 strain HG52. ICP34.5 and ICP47 genes were deleted to ensure abortive infection and immune destruction in normal cells. Bispecific T cell engager of anti-CD3 antibody and anti-PD-L1 antibody were constructed and inserted into HG52 strain genome.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Maximal tolerable doseTime frame: 2 months after initiation of enrollment
  2. Rate and grade of adverse eventsTime frame: From enrollment to 90 days after last treatment of all subjects
  3. Cope numbers of BS-006Time frame: 1 hours predose and 0.5 hours post-dose for first three doses and 1 hours predose ever after

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Zhongnan Hospital of Wuhan University

    Wuhan, Hubei, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.